Boudewijn van Vliet
Direktor/Vorstandsmitglied bei PRYME N.V.
Aktive Positionen von Boudewijn van Vliet
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
PRYME N.V. | Direktor/Vorstandsmitglied | 11.02.2021 | - |
Finanzdirektor/CFO | - | - | |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Direktor/Vorstandsmitglied | 09.08.2023 | - |
Vorsitzender | - | 09.08.2023 |
Karriereverlauf von Boudewijn van Vliet
Statistik
International
Niederlande | 2 |
Schweiz | 2 |
Operativ
Director/Board Member | 2 |
Director of Finance/CFO | 1 |
Chairman | 1 |
Sektoral
Industrial Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PRYME N.V. | Industrial Services |
Private Unternehmen | 1 |
---|---|
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Antion Biosciences SA is a Swiss-based biotechnology company that develops universal cell and gene therapy products to treat diseases with significant unmet medical needs. The private company is based in Geneva, Switzerland. The company's proprietary gene silencing and co-expression gene constructs allow for a modular and tunable approach to multiplex engineering of therapeutic cells. Antion aims to develop off-the-shelf therapies with enhanced potency and improved safety to make cell and gene therapies universal and broaden access to these life-changing therapies for all patients. Antion Biosciences was founded by Michael Pepper and Roberto Speck, and the CEO is Marco Alessandrini. | Health Technology |
- Börse
- Insiders
- Boudewijn van Vliet
- Erfahrung